A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A phase 2 trial of Amivantamab, Lazertinib, Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Janssen Research & Development, LLC, now recruiting.
Overview
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06667076 by Janssen Research & Development, LLC, with 480 participants planned, started 2024-12-16 and due to reach its primary completion in 2029-05-23. Interventions recorded: Amivantamab, Lazertinib, Chemotherapy: Pemetrexed and Chemotherapy: Carboplatin.
Similar pages
not linked directly; found by shared links- TrialA Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Shares Lazertinib, Amivantamab, Johnson & Johnson, Pemetrexed and the tag pipeline.
- TrialA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Shares Lazertinib, Amivantamab, Johnson & Johnson, Pemetrexed and the tag pipeline.
- TrialA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Shares Lazertinib, Amivantamab, Johnson & Johnson, Pemetrexed and the tag pipeline.
- TrialA Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Shares Amivantamab, Johnson & Johnson, Pemetrexed, Carboplatin and the tag pipeline.
- TrialEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Shares Lazertinib, Amivantamab, Johnson & Johnson, Non-small-cell lung cancer and the tag pipeline.
- TrialPremedication to Reduce Amivantamab Associated Infusion Related Reactions
Shares Lazertinib, Amivantamab, Johnson & Johnson, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Shares Amivantamab, Johnson & Johnson, Carboplatin and the tag pipeline.
- TrialA Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.